Unique ID issued by UMIN | UMIN000006155 |
---|---|
Receipt number | R000007279 |
Scientific Title | Evaluation of Aboral Pouch Reconstruction After Total Gastrectomy in Patients with Gastric Cancer : A Prospective Randomized Controlled Trial |
Date of disclosure of the study information | 2011/08/16 |
Last modified on | 2017/02/17 13:39:10 |
Evaluation of Aboral Pouch Reconstruction After Total Gastrectomy in Patients with Gastric Cancer : A Prospective Randomized Controlled Trial
CCOG1101
Evaluation of Aboral Pouch Reconstruction After Total Gastrectomy in Patients with Gastric Cancer : A Prospective Randomized Controlled Trial
CCOG1101
Japan |
Gastric cancer
Gastrointestinal surgery |
Malignancy
NO
The aboral pouch reconstruction is compared with simple Roux-en-Y reconstruction in a randomized controlled trial to identify the optimal reconstruction procedure after total gastrectomy for patients with gastric cancer.
Safety,Efficacy
Phase III
Assessment of Quality of Life after Total Gastrectomy
Body weight
Nutritional status
Operation time
Blood loss during the operation
Surgical complications
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Maneuver |
A: Roux-en-Y reconstruction
B: Aboral pouch reconstruction
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1st inclusion criteria (before surgery)
1) Histologically proven primary gastric adenocarcinoma
2) Candidate for R0 surgery by total gastrectomy for patients with gastric cancer
3) Length of esophageal invasion less than or equal to 3cm with no need for thoracotomy for resection
4) Borrmann type 4 and large (8cm or more in diameter) type 3 excluded
5) Not cancer of the remnant stomach
6) No history of upper abdominal surgery and no history of intestinal resection
7) No prior treatment of chemotherapy or radiation therapy against any other malignancies
8) Age 20 to 80 years old
9) PS (ECOG) of 0 or 1
10) Adequate organ functions for gastrectomy
11) Written informed consent from the patient
2nd inclusion criteria (during surgery)
1) cT1 - cT4a
2) cN0-2 H0 P0 M0
3) R0 resection possible, or R1 resection due only to CY1
4) No need for thoracotomy
1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ
2) Body mass index more than 28
3) Uncontrollable hypertension or uncontrollable diabetes mellitus
4) Continuous systemic steroid therapy
5) Otherwise considered inadequate for inclusion in this trial by the physician
90
1st name | |
Middle name | |
Last name | Yasuhiro Kodera |
Nagoya University Graduate School of Medicine
Department of Surgery II
65 Tsurumai-cho, Showa-ku, Nagoya, Japan
052-744-2250
miyuki.a@med.nagoya-u.ac.jp
1st name | |
Middle name | |
Last name | Yuichi Ito |
Aichi Cancer Center Hospital
Department of Gastroenterological Surgery
1-1 Kanokoden, Chikuda-ku, Nagoya, Japan
052-762-6111
yuichi@aichi-cc.jp
Chubu Clinical Oncology Group (CCOG)
Chubu Clinical Oncology Group (CCOG)
Self funding
NO
2011 | Year | 08 | Month | 16 | Day |
Published
Main results already published
2011 | Year | 06 | Month | 22 | Day |
2011 | Year | 08 | Month | 01 | Day |
2011 | Year | 08 | Month | 12 | Day |
2017 | Year | 02 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007279